22:05 , Jun 1, 2018 |  BioCentury  |  Finance

Bacterial brain

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B. The round closed on May 31...
20:03 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Sequoia leads Cortexyme's $76M series B

Alzheimer’s disease company Cortexyme Inc. (South San Francisco, Calif.) raised $76 million in a series B round led by Sequoia Capital. Fellow new investors included Vulcan Capital, Verily Life Sciences LLC (South San Francisco, Calif.),...
12:02 , May 31, 2018 |  BC Extra  |  Financial News

Sequoia leads Cortexyme's $76M series B

Alzheimer’s disease company Cortexyme Inc. (South San Francisco, Calif.) raised $76 million in a series B round led by Sequoia Capital. Fellow new investors included Vulcan Capital, Verily Life Sciences LLC (South San Francisco, Calif.),...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Financial News

3Scan completes venture financing

3Scan , San Francisco, Calif.   Business: Supply/Service   Date completed: 2016-07-11   Type: Venture financing   Raised: $14 million   Investors: Lux Capital; Data Collective; Dolby Family Ventures; OS Fund; Comet Labs; Breakout Ventures;...
01:01 , Jul 12, 2016 |  BC Extra  |  Financial News

Computational pathology play 3Scan raises $14M

3Scan (San Francisco, Calif.) raised $14 million in a series B round led by existing investors Lux Capital and Data Collective. Also participating were the investment arm of an undisclosed U.S. research hospital, existing investor...